With the results of the effector cell-to-target cell coculture tests, this indicates that SRE efficiently enhanced tumor-infiltrating CD8+ T cell activation via blockade of PD-1/PD-L1 interaction in the CRC tumor microenvironment. The gene discussed is CD8A; the disease is neoplasm.